Hematopoietic stem cells for refractory myasthenia gravis
The aim of this study is to assess the safety and feasibility of autologous peripheral hematopoietic stem cell transplantation in patients with refractory myasthenia gravis following patient conditioning with a high dose cyclophosphamide and anti-thymocyte globulin.
Read More
In patients with low yield of peripheral blood stem cells, bone marrow was subsequently harvested.
Read More
Product Information for
Hematopoietic stem cells for refractory myasthenia gravis